Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist or pharmacy technician CE statement of credit with ACPE UAN 0221-0000-20-413-L04-P/T), you are NOT allowed to also receive credit for this home-study on-demand web activity.
Biologic drugs have been increasingly viewed as the future of medicine. This activity is designed to increase your understanding of the biosimilar, including a review of biologic medications, history, spending and usage. Strategies for implementation of biosimilars will provide key take-aways for pharmacists and pharmacy technicians.
The target audience for this activity is pharmacists and pharmacy technicians. Upon completion of this activity, participants will be able to:
- Describe the difference between biologic medications and small molecule chemical medications.
- Explain the definitions of reference product, biosimilar product, and an interchangeable product.
- Explain the differences between a reference product, a biosimilar product, and an interchangeable product.
- Outline the abbreviated approval pathway for biosimilar and interchangeable products.
- List at least three major challenge biosimilars face in the US market.
- List at least three strategies a healthcare system can use to work around the challenges.
Sophia Z. Humphreys, Pharm.D., MHA
Director, System Pharmacy Clinical Services
Providence St. Joseph Health
Release Date: September 30, 2020
Expiration Date: September 30, 2023
Pharmacists and Pharmacy Technicians
This activity is provided by ProCE, Inc. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-20-413-H04-P/T has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Humphreys is a speaker and Advisory Board member for Coherus BioSciences.
This activity is supported by an educational grant from ECRM.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.